Amgen climbs after CVOT readout

Amgen Inc. (NASDAQ:AMGN) rose $7.95 to $167.53 on Friday, adding about $5.9 billion in market cap, after the company said Repatha evolocumab met the primary endpoint in the Phase III FOURIER cardiovascular outcomes trial.

Read the full 345 word article

User Sign In